Literature DB >> 17900841

Focal liver lesions: role of contrast-enhanced ultrasound.

Thomas Rettenbacher1.   

Abstract

The introduction of microbubble contrast agents and the development of contrast-specific techniques have opened new possibilities in liver imaging. Initially, only intermittent imaging with Doppler detection was available. Second-generation contrast agents and low mechanical index real-time scanning techniques are decisive advances that enable convenient liver examinations with high sensitivity and specificity. Hepatic lesions usually show typical perfusion and enhancement patterns through the various contrast phases, which help their characterization. Several published studies and the daily clinical routine show that, as opposed to conventional ultrasound (US), contrast-enhanced US can substantially improve detection and differentiation of focal liver lesions. Today, contrast-enhanced US is the dynamic imaging modality of choice for differentiation of focal liver lesions. Contrast uptake patterns of the most relevant liver lesions, as well as important clinical indications are presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900841     DOI: 10.1016/j.ejrad.2007.07.026

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  12 in total

1.  Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies.

Authors:  Wen Luo; Kazushi Numata; Manabu Morimoto; Akito Nozaki; Michio Ueda; Masaaki Kondo; Satoshi Morita; Katsuaki Tanaka
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

Review 2.  Endoscopic ultrasound advances, part 1: diagnosis.

Authors:  Edward Kim; Jennifer J Telford
Journal:  Can J Gastroenterol       Date:  2009-09       Impact factor: 3.522

3.  Contrast-enhanced ultrasound for characterisation of hepatic lesions appearing non-hypervascular on CT in chronic liver diseases.

Authors:  H Maruyama; M Takahashi; H Ishibashi; M Yoshikawa; O Yokosuka
Journal:  Br J Radiol       Date:  2011-01-11       Impact factor: 3.039

4.  Hyperechogenic liver lesion.

Authors:  George Saraci; Anamaria Truta
Journal:  Maedica (Bucur)       Date:  2011-07

5.  Contrast ultrasound in hepatocellular carcinoma at a tertiary liver center: First Indian experience.

Authors:  Shalini Thapar Laroia; Simranjeet Singh Bawa; Deepak Jain; Amar Mukund; Shiv Sarin
Journal:  World J Radiol       Date:  2013-06-28

6.  Visualization of Small-Diameter Vessels by Reduction of Incoherent Reverberation With Coherent Flow Power Doppler.

Authors:  You Leo Li; Dongwoon Hyun; Lotfi Abou-Elkacem; Juergen Karl Willmann; Jeremy J Dahl
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2016-11       Impact factor: 2.725

7.  Perfusion pattern of musculoskeletal masses using contrast-enhanced ultrasound: a helpful tool for characterisation?

Authors:  Alexander Loizides; Siegfried Peer; Michaela Plaikner; Tanja Djurdjevic; Hannes Gruber
Journal:  Eur Radiol       Date:  2012-03-13       Impact factor: 5.315

8.  Contrast-enhanced ultrasonography parameters in neural network diagnosis of liver tumors.

Authors:  Costin Teodor Streba; Mihaela Ionescu; Dan Ionut Gheonea; Larisa Sandulescu; Tudorel Ciurea; Adrian Saftoiu; Cristin Constantin Vere; Ion Rogoveanu
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

9.  Imaging features of hepatic angiomyolipomas on real-time contrast-enhanced ultrasound.

Authors:  Z Wang; H-X Xu; X-Y Xie; X-H Xie; M Kuang; Z-F Xu; G-J Liu; L-D Chen; M-X Lin; M-D Lu
Journal:  Br J Radiol       Date:  2009-09-01       Impact factor: 3.039

Review 10.  Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions.

Authors:  Jae Young Jang; Moon Young Kim; Soung Won Jeong; Tae Yeob Kim; Seung Up Kim; Sae Hwan Lee; Ki Tae Suk; Soo Young Park; Hyun Young Woo; Sang Gyune Kim; Jeong Heo; Soon Koo Baik; Hong Soo Kim; Won Young Tak
Journal:  Clin Mol Hepatol       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.